Chemokine receptor antagonism as a new therapy for multiple sclerosis.
New information about the role of tissue inflammation in the pathogenesis of multiple sclerosis (MS) has driven a search for effective and specific therapeutics that address leukocyte trafficking. These developments in understanding MS are complemented by advances in clarifying the molecular mechanisms of leukocyte extravasation and providing the knowledge base needed to modulate tissue inflammation. Of particular interest are the chemokines and their receptors. Chemokines constitute a large family of chemoattractant peptides that regulate the vast spectrum of leukocyte migration events. This review discusses MS and proposes that identifying the chemokines and receptors involved in the inflammation associated with this disorder may lead to therapeutic intervention.
Ransohoff
R M
RM
The Lerner Research Institute, Cleveland Clinic Foundation, NC30, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
Bacon
K B
KB
D000818:Animals; D018925:Chemokines / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D019707:Receptors, Chemokine / Q000037:antagonists & inhibitors* / Q000235:genetics
D018925:Chemokines; D019707:Receptors, Chemokine